Figure S1, Electronic Supplementary Material


Figure S1: *lasR* mutations are beneficial.

The competitive fitness (mean ± s.e; n=3) of three initial *rpoB* mutants (blue diamonds) and three evolved endpoint clones (red squares) with single point mutations in the *lasR* gene were determined relative to the rifampicin-sensitive ancestral strain. Stop-gain mutations in *lasR* are denoted by the * symbol. All three evolved endpoint clones showed an increase in average competitive fitness compared to their ancestral *rpoB* mutants, two of which are statistically significant (two-sample t-test, *P* < 0.05).